Sugi Predict

Sugi Predict / Compounds / Hydrangeaic Acid

Hydrangeaic Acid

Hydrangeaic Acid

SCHEMBL5352105

O=C(O)c1c(O)cccc1/C=C/c1ccc(O)cc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.53
▸ CA12 O43570 2/20 0.52
▸ CA1 P00915 2/20 0.52
▸ CA2 P00918 2/20 0.52
▸ CA7 P43166 2/20 0.52
▸ CA9 Q16790 2/20 0.52
▸ CA14 Q9ULX7 2/20 0.52
▸ TRPA1 O75762 1/20 0.50
▸ NFE2L2 Q16236 1/20 0.49
▸ PKM P14618 2/20 0.46
▸ TYR P14679 2/20 0.46
▸ AKR1B10 O60218 1/20 0.46
▸ ESR1 P03372 1/20 0.46
▸ CA3 P07451 1/20 0.46
▸ AKR1B1 P15121 1/20 0.46
▸ CA4 P22748 1/20 0.46
▸ CA6 P23280 1/20 0.46
▸ DPP4 P27487 1/20 0.46
▸ CA5A P35218 1/20 0.46
▸ HCAR2 Q8TDS4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrangeaic Acid SCHEMBL5352111 1.00 TTR (0.53) TTRCA12CA1CA2CA7
Hydrangeaic Acid SCHEMBL12204951 1.00 TTR (0.53) TTRCA12CA1CA2CA7
SCHEMBL30477514 0.90 TRPA1 (0.63) TTRCA12CA1CA2CA7
SCHEMBL1647970 0.90 TRPA1 (0.63) TTRCA12CA1CA2CA7
SCHEMBL21530613 0.90 TRPA1 (0.63) TTRCA12CA1CA2CA7
SCHEMBL20594072 0.84 LCK (0.53) TTRCA12CA1CA2CA7
SCHEMBL23718096 0.81 KAT8 (0.49) CA12CA1CA2CA7CA9
SCHEMBL20333014 0.80 RELA (0.51) CA12CA1CA2CA7CA9
SCHEMBL26639076 0.80 RELA (0.51) CA12CA1CA2CA7CA9
SCHEMBL26727059 0.80 PTPN1 (0.62) TTRCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747367-A1 NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES Symrise AG (DE) 2026-05-27 — — EP claimed
WO-2025017042-A1 NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES SYMRISE AG (DE) 2025-01-23 — — WO claimed
EP-1311258-B1 COMPOSITIONS CONTAINING HYPOTRIGLYCERIDEMICALLY ACTIVE STILBENOIDS INSMED INC (US) 2005-04-06 — — EP claimed
EP-1311258-A2 COMPOSITIONS CONTAINING HYPOTRIGLYCERIDEMICALLY ACTIVE STILBENOIDS Insmed Incorporated (US) 2003-05-21 — — EP claimed
US-6541522-B2 Including longistyline A-2-carboxylic acid as a dietary supplement INSMED INCORPORATED 2003-04-01 — — US claimed
US-20020058708-A1 Compositions containing hypotriglyceridemically active stilbenoids SHAMAN PHARMACEUTICALS 2002-05-16 — — US claimed
US-20020055541-A1 Compositions containing hypotriglyceridemically active stilbenoids SHAMAN PHARMACEUTICALS, INC. 2002-05-09 — — US claimed
WO-2002013809-A2 COMPOSITIONS CONTAINING HYPOTRIGLYCERIDEMICALLY ACTIVE STILBENOIDS INSMED INCORPORATED (US) 2002-02-21 — — WO claimed
WO-2002013806-A2 COMPOSITIONS CONTAINING HYPOTRIGLYCERIDEMICALLY ACTIVE STILBENOIDS INSMED INCORPORATED (US) 2002-02-21 — — WO claimed
EP-4747367-A1 NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES Symrise AG (DE) 2026-05-27 — — EP disclosed
WO-2026084556-A1 HYDRANGEA EXTRACT AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING, ALLEVIATING, OR TREATING PERIODONTITIS 벨아벨바이오 주식회사 2026-04-23 — — WO disclosed
WO-2025017042-A1 NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES SYMRISE AG (DE) 2025-01-23 — — WO disclosed
US-20250000127-A1 PREPARATION OF DRIED PLANT MATERIAL HAVING AN INCREASED CONTENT OF PHYLLODULCIN SYMRISE AG (DE) 2025-01-02 — — US disclosed
US-20240407385-A1 HIGH PURITY PHYLLODULCIN EXTRACT SYMRISE AG (DE) 2024-12-12 — — US disclosed
US-6541522-B2 Including longistyline A-2-carboxylic acid as a dietary supplement INSMED INCORPORATED 2003-04-01 — — US disclosed
US-20020058708-A1 Compositions containing hypotriglyceridemically active stilbenoids SHAMAN PHARMACEUTICALS 2002-05-16 — — US disclosed
US-20020055541-A1 Compositions containing hypotriglyceridemically active stilbenoids SHAMAN PHARMACEUTICALS, INC. 2002-05-09 — — US disclosed
WO-2002013806-A2 COMPOSITIONS CONTAINING HYPOTRIGLYCERIDEMICALLY ACTIVE STILBENOIDS INSMED INCORPORATED (US) 2002-02-21 — — WO disclosed
WO-2002013809-A2 COMPOSITIONS CONTAINING HYPOTRIGLYCERIDEMICALLY ACTIVE STILBENOIDS INSMED INCORPORATED (US) 2002-02-21 — — WO disclosed
EP-1161944-A1 DRUGS, FOODS AND ORAL COMPOSITIONS CONTAINING STILBENE-TYPE COMPOUNDS Sunstar Inc. (JP) 2001-12-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058708-A1 Compositions containing hypotriglyceridemically active stilbenoids CPT1B, CPT1A, LIPC TTR 1446/4885CA12 4765/4885CA1 4285/4885
US-20020055541-A1 Compositions containing hypotriglyceridemically active stilbenoids CPT1B, CPT1A, LIPC TTR 1446/4885CA12 4765/4885CA1 4285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.